A Phase Ib/2 Basket Study of ACR-368 Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma and Urothelial Carcinoma Based on Acrivon OncoSignature Status. Trial type: Ovarian, Endometrial, Bladder.